Key insights
- BofA Securities lowered its price target on BioNTech (BNTX) to $125 from $130 due to a revenue miss in Q1. While maintaining a Buy rating, the firm acknowledges analyst concerns about declining sales and recent unprofitability. The company is expanding its oncology franchise and has several clinical readouts expected this year. Overall, this news has a slightly negative impact on US equities due to the reduced price target, but the maintained Buy rating limits the downside.
Investing.com - BofA Securities lowered its price target on BioNTech (NASDAQ:BNTX) to $125 from $130 while maintaining a Buy rating on the shares.
The company reported first-quarter revenue of €118 million, missing the consensus estimate of €171 million. BofA Securities had projected €109 million for the quarter. The stock currently trades at $95.96 with a market cap of $24.3 billion. According to InvestingPro Tips, analysts anticipate sales decline in the current year, and the company was not profitable over the last twelve months with an EPS of -$5.52.
BioNTech initiated five new pivotal trials for pumitamig in the first quarter and continues to expand its combination therapy strategy in oncology. The company reaffirmed its fiscal 2026 revenue guidance of €2 billion to €2.3 billion, including approximately €613 million from its collaboration with Bristol Myers Squibb. InvestingPro analysis suggests the stock appears slightly undervalued based on its Fair Value assessment. Investors can access comprehensive analysis through the Pro Research Report, available for BNTX and 1,400+ other US equities.
BofA Securities noted the company is searching for a new chief executive officer and chief medical officer to help manage its growing oncology franchise. The firm expects several clinical readouts for pumitamig this year.
The research firm maintains a bullish view on the commercial opportunity for pumitamig and reiterated its Buy rating with the new $125 price target.
In other recent news, BioNTech has been the subject of several analyst assessments and company announcements. H.C. Wainwright reiterated its Buy rating for BioNTech, maintaining a price target of $130, following trial data presented by Merck on a PD-1xVEGF bispecific antibody. Similarly, BofA Securities raised its price target for BioNTech to $130 from $128, citing positive phase 2 data for T-Pam, a HER2-targeted antibody-drug conjugate in endometrial cancer. Conversely, Leerink Partners lowered its price target to $94 from $113, expressing concerns about the outlook for BioNTech’s next-generation CTLA-4 gotistobart, particularly in the Phase 3 PRESERVE-003 study.
Additionally, H.C. Wainwright adjusted its price target for BioNTech to $130 from $140, while still maintaining a Buy rating, based on Phase 2 results for pumitamig presented at a recent congress. In corporate developments, BioNTech announced its 2026 Annual General Meeting scheduled for May 15, with details included in a U.S. Securities and Exchange Commission filing. The agenda for the meeting has not been disclosed in detail. These recent developments reflect a mix of optimism and caution among analysts regarding BioNTech’s ongoing clinical trials and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.